We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals

255 hedge funds and large institutions have $1.15B invested in Aurinia Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 88 increasing their positions, 82 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more funds holding in top 10

Funds holding in top 10: 14 (+3)

93% more call options, than puts

Call options by funds: $22M | Put options by funds: $11.4M

58% more capital invested

Capital invested by funds: $730M → $1.15B (+$423M)

50% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 30

5% more funds holding

Funds holding: 242255 (+13)

4.87% more ownership

Funds ownership: 50.17%55.04% (+4.9%)

7% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 82

Holders
255
Holders Change
+13
Holders Change %
+5.37%
% of All Funds
3.1%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.05%
New
45
Increased
88
Reduced
82
Closed
30
Calls
$22M
Puts
$11.4M
Net Calls
+$10.6M
Net Calls Change
+$3.32M

AUPH Hedge Fund Activity: Q4 2025 in Review

255 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2025, worth a combined $1.15B — up 58% from $730M a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new AUPH positions and 30 closed out — a net gain of 15 holders — while 88 added to existing stakes and 82 trimmed.

The largest buyer was Nomura Holdings, adding an estimated $11.9M. The largest seller was Jump Financial, cutting an estimated $5.22M.

  • 255 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2025, up from 242 in Q3 2025.
  • Funds reported $1.15B of Aurinia Pharmaceuticals stock for Q4 2025, up 58% quarter-over-quarter.
  • 45 funds opened new Aurinia Pharmaceuticals positions in Q4 2025 and 30 closed out, a net change of +15 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q4 2025 was Nomura Holdings, an estimated $11.9M added.
  • The largest Aurinia Pharmaceuticals seller in Q4 2025 was Jump Financial, an estimated $5.22M sold.

Based on aggregated 13F filings for Q4 2025.